


Boosting Europe's competitiveness and scientific leadership



EDCTP's added
value for Europe



EDCTP strengthens Europe's competitiveness by fostering research excellence and global cooperation to advance health innovations.


EDCTP's geographical and technological scope opens opportunities for European companies to expand into new markets and contribute to global health solutions.



Scan
for more
info

EDCTP's added value for Europe

Protecting Europe through stronger global health security cooperation



EDCTP's added
value for Europe



EDCTP contributes to Europe's health security by addressing climate-sensitive infectious disease threats and antimicrobial resistance.


EDCTP has also demonstrated exceptional agility in responding to health crises and outbreaks.



Scan
for more
info

EDCTP's added value for Europe

Spearheading Europe's science diplomacy through equitable partnerships



EDCTP's added
value for Europe



EDCTP is the largest and most established research partnership between Europe and Africa.

EDCTP's funding and governance are based on joint Africa-Europe ownership.

EDCTP ensures that research consortia operate equitably and uphold high ethical scientific standards.



Scan
for more
info

EDCTP's added value for Europe

Leveraging Europe's digital talent for public health solutions



EDCTP's added
value for Europe



EDCTP reinforces Europe's strategic leadership for digital transformation and smarter responses to health challenges by investing in digital and AI technologies in health.

EDCTP also advances the implementation of key international strategies in digital health transformation.

EDCTP creates collaboration and investment opportunities for European companies by supporting digital capacity and innovation in Africa.



Scan
for more
info

EDCTP's added value for Europe

Advancing Europe's human rights commitment at the global and local levels



EDCTP's added
value for Europe



EDCTP contributes to the EU's commitment to human rights by addressing unmet medical needs, promoting gender equality and research equity, and delivering life-saving health technologies for vulnerable populations.


EDCTP promotes an inclusive innovation ecosystem and prioritises ethical research that responds to historically neglected populations.



Scan
for more
info

EDCTP's added value for Europe

Boosting Africa's prosperity through better health and wellbeing



EDCTP's added
value for Africa



EDCTP is dedicated to reducing Africa's infectious disease burden by funding clinical research and strengthening local capacity.


EDCTP strengthens African health research systems and empowers local professionals to tackle the continent's health priorities.



Scan
for more
info

EDCTP's added value for Africa

Contributing to Africa's health security and sovereignty



EDCTP's added
value for Africa



EDCTP contributes to Africa's health security by supporting clinical research, training, and networks for epidemic preparedness and response.

EDCTP supports Africa's response to health threats, including Ebola, mpox, COVID-19, Lassa fever, and climate change- and AMR-related outbreaks.



Scan
for more
info

EDCTP's added value for Africa

Enhancing Africa's clinical research ecosystems



EDCTP's added
value for Africa



Boosting clinical research across the continent is key to improving health outcomes and social and economic development. EDCTP has enhanced clinical research ecosystems in Africa by supporting over 3,000 researchers and health professionals.


EDCTP has supported the establishment of the Pan African Clinical Trials Registry (PACTR), which became a WHO Primary Clinical Trials Registry.



Scan
for more
info

EDCTP's added value for Africa

Advancing health partnerships within Africa and with Africa



EDCTP's added
value for Africa



EDCTP advances health partnerships in Africa by aligning research, investments and interventions with the continent's priorities.

As a key implementing partner of the European Union–African Union Innovation Agenda, EDCTP helps align policy, research and innovation systems between Europe and Africa.



Scan
for more
info

EDCTP's added value for Africa

Driving health equity and trust in Africa



EDCTP's added
value for Africa



EDCTP drives health equity by prioritising underserved populations – including women, newborns and children, poor people and rural communities – helping accelerate Africa's progress towards Universal Health Coverage.

Equity and trust guide EDCTP's work: research and resulting technologies are required to be accessible, acceptable, and gender-responsive, developed with high ethical standards and active community participation.




Scan
for more
info

EDCTP's added value for Africa

First-ever malaria vaccines

**European
Medicines
Agency's
positive opinion**

**WHO-
prequalified**



EDCTP's support for this medicine included:

- Funding for research & development
- Capacity & infrastructure building
- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medical solutions
already saving and improving lives



What it is

RTS,S and R21/Matrix-M are the first vaccines developed to prevent malaria, and the first vaccines against a human parasitic disease to be recommended for widespread use. Both vaccines target *Plasmodium falciparum*, the parasite responsible for most malaria cases and deaths in Africa, helping the immune system prevent the parasite from infecting the liver.

Why it matters

Malaria remains a major public health threat in sub-Saharan Africa, particularly for young children. In 2024, 282 million people fell ill with malaria and 610,000 died, with 95% of deaths occurring in the WHO African Region. RTS,S and R21/Matrix-M vaccines could prevent millions of illnesses and save thousands of children every year.




Scan
for more
info

New and better medical solutions

First malaria treatment for newborns and young infants

WHO-
prequalified



EDCTP's support for this medicine included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Facilitating access & rollout
- Funding for further innovation & optimisation

New and better medical solutions
already saving and improving lives



What it is

Coartem® Baby is the first approved malaria treatment specifically designed for newborns and young infants weighing 2 to 5 kg. It is a dissolvable tablet that can be mixed with breast milk, has a sweet cherry flavour to make administration easier and delivers precise dosing.

Why it matters

Malaria is a leading cause of child mortality in Africa. For decades, no approved medicine existed for babies in this weight range, and clinicians had no choice but to use formulations intended for older children, increasing the risk of dosing errors and toxicity. Coartem® Baby fills this long-standing gap.



Scan
for more
info

New and better medical solutions

Ensuring children have appropriate HIV treatment



EDCTP's support for this medicine included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medical solutions
already saving and improving lives

What it is

Triomune Baby/Junior became the first fixed-dose combination medicine developed specifically for children with HIV and paved the way for additional improved combination therapies for first- and second-line HIV treatment in children.

Why it matters

While antiretroviral therapy (ART) is lifesaving against HIV, existing formulations are often unsuitable for babies and children. These innovations enhance the acceptability and use of ART in children, helping to save and improve their lives.




Scan
for more
info

New and better medical solutions

A unique medicine for worm infections in children

**European
Medicines
Agency's
positive opinion**



EDCTP's support for this medicine included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Facilitating access & rollout
- Funding for further innovation & optimisation

New and better medical solutions
already saving and improving lives



What it is

This new fixed-dose combination therapy of albendazole/ivermectin targets five types of parasitic worms (four soil-transmitted helminth infections and lymphatic filariasis), which will significantly improve the efficiency and cost-effectiveness of large-scale interventions.

Why it matters

Soil-transmitted helminths and lymphatic filariasis are neglected diseases affecting one in four people worldwide and leaving children nutritionally and physically impaired. This new treatment will enhance the effectiveness of public health interventions against these parasites, benefiting millions worldwide.



Scan
for more
info

New and better medical solutions

The first medicine against schistosomiasis for pre-school children

**European
Medicines
Agency's
positive opinion**

**WHO-
prequalified**



EDCTP's support for this medicine included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Facilitating access & rollout
- Funding for further innovation & optimisation

New and better medical solutions
already saving and improving lives



What it is

Arpraziquantel is the first child-friendly medicine in an oro-dispersible formulation to treat and cure schistosomiasis. It is easy to administer and adapted for rural and tropical settings, offering high efficacy with minimal side effects.

Why it matters

Schistosomiasis affects around 240 million people worldwide and severely harms children's physical and cognitive development. This innovation could protect and improve the lives of 50 million children currently at risk.



Scan
for more
info

New and better medical solutions

Patient-friendly oral treatments for sleeping sickness

**European
Medicines
Agency's
positive opinion**

**WHO-
prequalified:
Fexinidazole
Winthrop**



EDCTP's support for this medicine included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medical solutions
already saving and improving lives



What it is

Fexinidazole Winthrop and Acoziborole Winthrop are two revolutionary oral treatments for human African trypanosomiasis (HAT), commonly known as sleeping sickness. Fexinidazole Winthrop, taken as pills over 10 days, is the first all-oral therapy, while Acoziborole Winthrop is the first single-dose one-day oral therapy.

Why it matters

Although sleeping sickness is nearing eradication, it persists in the poorest and most remote areas of Africa, where delivering care is a significant challenge. The disease is usually fatal without treatment, making this patient-friendly innovation essential.




Scan
for more
info

New and better medical solutions

A simpler treatment for HIV-associated cryptococcal meningitis

WHO-
recommended



EDCTP's support for this treatment included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medical solutions
already saving and improving lives



What it is

This new therapy, a single high dose of liposomal amphotericin B, is as effective as the traditional week-long regimen, easier to administer, and causes fewer side effects. It is now the WHO-recommended therapy for cryptococcal meningitis.

Why it matters

Despite highly effective HIV treatments, opportunistic infections such as cryptococcal meningitis continue to cause significant morbidity and mortality, accounting for around 200,000 AIDS-related deaths annually. This new therapy can help save lives and improve the health of people living with HIV.




Scan
for more
info

New and better medical solutions

Reducing deaths from a serious HIV complication through early screening and treatment

WHO-
recommended



EDCTP's support for this approach included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medical solutions
already saving and improving lives



What it is

A simple, three-part package combining screening, preventive treatment and community adherence support that significantly cuts deaths among people starting HIV treatment with advanced disease.

Why it matters

Cryptococcal meningitis can kill within days and often goes undetected until too late, making the start of HIV treatment one of the most dangerous moments for people with advanced disease. Before the REMSTART trial, routine clinics had no simple way to catch it early.




Scan
for more
info

New and better medical solutions

Fast, effective, and easy-to-use treatment for uncomplicated malaria

**European
Medicines
Agency's
marketing
authorisation**

**WHO-
prequalified**



EDCTP's support for this medicine included:

- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medical solutions
already saving and improving lives



What it is

Eurartesim® is a fixed-dose artemisinin-based combination therapy (ACT) containing dihydroartemisinin-piperaquine (DHAPQ) for the treatment of uncomplicated malaria.

Why it matters

It helps address critical gaps in malaria treatment by providing a well-tolerated, easy-to-administer therapy that reduces both treatment failure and reinfection rates. It is suitable for children, who remain among the most vulnerable to malaria.




Scan
for more
info

New and better medical solutions

Bringing rapid tuberculosis diagnosis to the front lines of care

WHO-
recommended



EDCTP's support for this diagnostic tool included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medical solutions
already saving and improving lives



What it is

Molbio Truenat is a portable, battery-powered molecular diagnostic tool for tuberculosis (TB) testing directly in primary health care settings. It delivers rapid and reliable results for adults with pulmonary TB symptoms, making advanced diagnosis possible even in the most remote and low-resource settings.

Why it matters

Tuberculosis is the world's deadliest infectious disease, with around 10 million people falling ill every year. Early and accurate diagnosis is essential to interrupt transmission and prevent health problems. With point-of-care molecular testing, patients can receive results and begin treatment on the same day.



Scan
for more
info

New and better medical solutions

Expanding the reach of an established malaria treatment for patients with limited options

**European
Medicines
Agency's
positive opinion**



EDCTP's support for this medicine included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medical solutions
already saving and improving lives



What it is

Pyramax® is an established antimalarial medicine whose safety and efficacy have been progressively expanded through EDCTP-supported research to reach more patient groups who lack specific treatment options, including children, pregnant women and patients requiring re-treatment.

Why it matters

Malaria remains a leading cause of child mortality in Africa, and treatment options are still lacking for many priority populations. By supporting the evidence needed to extend proven medicines to new groups, EDCTP has helped ensure that more people can access safe, effective treatment.




Scan
for more
info

New and better medical solutions

Expanding the use of a common medicine to prevent dangerous HIV-TB inflammatory reaction

Included in
international
guidelines



EDCTP's support for this medicine included:

- Funding for research & development
- Funding for further innovation & optimisation

New and better medical solutions
already saving and improving lives



What it is

The PredART trial showed that prednisone, a common and inexpensive steroid drug used to treat TB-IRIS, can also be used to prevent it. In patients with both TB and HIV who start HIV therapy, a four-week course of prednisone has been shown to reduce the chance of developing this complication by about 30%.

Why it matters

In people living with HIV and tuberculosis, starting antiretroviral therapy (ART) can trigger TB-IRIS, a serious inflammatory reaction that can lead to hospitalisation or death. Before the PredART trial, there was no evidence-based way to prevent it.




Scan
for more
info

New and better medical solutions

Making breastfeeding safer for mothers living with HIV

WHO-
recommended



EDCTP's support for this treatment included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medical solutions
already saving and improving lives



What it is

A three-drug antiretroviral regimen given to HIV-positive women in late pregnancy and through breastfeeding cuts HIV transmission to babies safely, without requiring mothers to stop breastfeeding.

Why it matters

Breastfeeding was long seen as a major HIV transmission risk, yet avoiding it raised the risk of malnutrition, illness and unsafe feeding, especially where resources were limited. This trial showed the two risks didn't have to be traded off against each other.




Scan
for more
info

New and better medical solutions

Reaching more people in the fight against river blindness

**Approved by
Ghana and US
authorities**

**On WHO
Essential
Medicines Lists**



EDCTP's support for this medicine included:

- Funding for research & development
- Support for regulatory approval & policy improvement
- Funding for further innovation & optimisation

New and better medical solutions
already saving and improving lives



What it is

Research co-funded through EDCTP2 and continued under Global Health EDCTP3 has expanded the use of moxidectin, an oral treatment for river blindness, to children from four years old and generated evidence for repeated community-wide treatment.

Why it matters

Onchocerciasis affects millions across Africa and can cause disfiguring skin conditions and permanent blindness. Moxidectin is expected to speed up elimination by killing parasite larvae more effectively and for longer than ivermectin.



Scan
for more
info

New and better medical solutions